(Press-News.org) Biologists have long wondered if mammals share the elegant system used by insects, bacteria and other invertebrates to defend against viral infection. Two back-to-back studies in the journal Science last year said the answer is yes, but a study just published in Cell Reports by researchers at the Icahn School of Medicine at Mount Sinai found the opposite. In the Mount Sinai study, the results found that the defense system used by invertebrates — RNA interferences or RNAi — is not used by mammals as some had argued. RNAi are small molecules that attach to molecular scissors used by invertebrates to cut up invading viruses. Mammals use a form of RNAi to fine-tune the expression of hundreds of genes that coordinate development in the womb, says the study's senior author, Benjamin tenOever, PhD, Fishberg Professor in the Department of Medicine and Department of Microbiology at the Icahn School of Medicine at Mount Sinai. But it has never been clear that adult mammals use RNAi the same way that plants and insects do, he says. "Mammals have cell machinery that looks capable of producing RNAi to fight virus, but we believe it only helps to produce different small RNA products called microRNAs, which are not antiviral," Dr. tenOever says. The correct answer matters because RNAi is being studied as a potential basis for new kinds of drugs for the treatment of hemophilia, beta-thalassemia and many viral infections, says Dr. tenOever. "We believe our results settle a longstanding debate about whether mammals, including humans and mice, fight viruses using RNAi, and the answer is good news," he says. "Drug designers interested in using RNAi to treat disease have worried that if RNAi is part of the mammalian response to viral infections, RNAi-based agents could compromise a human's immune response, producing unintended consequences. That is not a concern now, based on our findings." Mammals are known to fend off viruses with a system based on interferons, signaling proteins made by immune cells that amplify the body's attack on invaders. The finding that mammals do not use RNAi to fight viruses suggests that RNAi-based drugs could augment the existing interferon response in mammals, Dr. tenOever says. "We could harness this potent RNAi viral-killing machine when natural human immunity isn't enough." To answer the question, a team of researchers from the Icahn Graduate School of Biomedical Science used a virus that produces oral lesions in cows and pigs. They eliminated the part of the virus that causes disease, rendering it harmless and susceptible to both RNAi and interferons. They then took this harmless virus and gave it the capacity to block either interferon or RNAi. In experiments with mice, when the virus was designed to block interferon, no immune defense occurred and the interferon-blocking virus flourished. In contrast, giving the virus the capacity to block RNAi, found that the animals mounted a robust interferon-based defense that further weakened the RNAi-blocking virus. The same thing happened when the RNAi-blocking virus was introduced to engineered mice that could not produce interferons. "If mammals used interferon and RNAi to fight the virus, we would have seen the RNAi-blocking virus flourish in at least this setting — but we did not," Dr. tenOever says. "This is the strongest published data that argues against recent claims that RNAi exists in mammals, he says. INFORMATION: Study co-authors include Mount Sinai researchers Simone Backes, PhD, Ryan Langlois, PhD, Sonja Schmid, PhD, Andrew Varble, PhD, Jaehee Shim and David Sachs. The study was supported in part by the U.S. Army Research Laboratory and the U.S. Army Research Office under grant numbers W911NF-12-R-0012 and W911NF-07-R-0003.
About the Mount Sinai Health System
The Mount Sinai Health System is an integrated health system committed to providing distinguished care, conducting transformative research, and advancing biomedical education. Structured around seven member hospital campuses and a single medical school, the Health System has an extensive ambulatory network and a range of inpatient and outpatient services—from community‐based facilities to tertiary and quaternary care.
The System includes approximately 6,600 primary and specialty care physicians, 12‐minority‐owned free‐standing ambulatory surgery centers, over 45 ambulatory practices throughout the five boroughs of New York City, Westchester, and Long Island, as well as 31 affiliated community health centers. Physicians are affiliated with the Icahn School of Medicine at Mount Sinai, which is ranked among the top 20 medical schools both in National Institutes of Health funding and by U.S. News & World Report.
For more information, visit http://www.mountsinai.org, or find Mount Sinai on Facebook, Twitter and YouTube.
Mammals defend against viruses differently than invertebrates
ELSE PRESS RELEASES FROM THIS DATE:
Many ER patients test positive for HIV while in most infectious stage
WASHINGTON — Human Immunodeficiency Virus (HIV) screening for emergency patients at an institution with a large number of ethnic minority, underinsured and uninsured people reveals few are HIV positive, but of those who are, nearly one-quarter are in the acute phase and more than one-quarter have infections that have already advanced to Acquired Immune Deficiency Syndrome (AIDS). The results of the study were reported online yesterday in Annals of Emergency Medicine ("Identification of Acute HIV Infection Using Fourth Generation Testing in an Opt-Out Emergency Department ...
Fatal cellular malfunction identified in Huntington's disease
Researchers believe they have learned how mutations in the gene that causes Huntington's disease kill brain cells, a finding that could open new opportunities for treating the fatal disorder. Scientists first linked the gene to the inherited disease more than 20 years ago. Huntington's disease affects five to seven people out of every 100,000. Symptoms, which typically begin in middle age, include involuntary jerking movements, disrupted coordination and cognitive problems such as dementia. Drugs cannot slow or stop the progressive decline caused by the disorder, which ...
Cocoa extract may counter specific mechanisms of Alzheimer's disease
(NEW YORK – June 23) A specific preparation of cocoa-extract called Lavado may reduce damage to nerve pathways seen in Alzheimer's disease patients' brains long before they develop symptoms, according to a study conducted at the Icahn School of Medicine at Mount Sinai and published June 20 in the Journal of Alzheimer's Disease (JAD). Specifically, the study results, using mice genetically engineered to mimic Alzheimer's disease, suggest that Lavado cocoa extract prevents the protein β-amyloid- (Aβ) from gradually forming sticky clumps in the brain, which ...
'Tom Sawyer' regulatory protein initiates gene transcription in a hit-and-run mechanism
A team of genome scientists has identified a "hit-and-run" mechanism that allows regulatory proteins in the nucleus to adopt a "Tom Sawyer" behavior when it comes to the work of initiating gene activation. Their research, which appears in the Proceedings of the National Academy of Sciences, focuses on transcription factors—proteins that orchestrate the flow of genetic information from DNA to messenger RNA (mRNA). Their results show how transcription factors (TFs) activate mRNA synthesis of a gene, and leave the scene – in a model termed "hit-and-run" transcription. "Much ...
Treading into a gray area along the spectrum of wood decay fungi
One of the most basic rules for playing the game "Twenty Questions" is that all of the questions must be definitively answered by either "yes" or "no." The exchange of information allows the players to correctly guess the item in question. Fungal researchers have been using a variation of Twenty Questions to determine if wood-decaying fungi fall under one of two general classes. If a fungus can break down all the components – cellulose, hemicellulose and lignin – of plant cell walls it is considered a white rot fungus. If a fungus can only break down cellulose and hemicellulose ...
Emergence of bacterial vortex explained
VIDEO: When confined in a water droplet, B. subtilis bacteria collectively and spontaneously form a swirling vortex, with some bacteria moving in one direction and others moving the opposite way. Researchers... Click here for more information. PROVIDENCE, R.I. [Brown University] — When a bunch of B. subtilis bacteria are confined within a droplet of water, a very strange thing happens. The chaotic motion of all those individual swimmers spontaneously organizes into a swirling ...
Straw albedo mitigates extreme heat
Wheat fields are often tilled immediately after the crop is harvested, removing the light-coloured stubble and crop residues from the soil surface and bringing dark bare earth to the top. Post-harvest tilling is a widely practised and common management technique in Europe. However, ploughed fields can have a negative effect on the local climate during a heat wave. This effect was addressed in a recent study conducted by researchers at ETH Zurich led by Edouard Davin, senior lecturer at the Institute for Atmospheric and Climate Science, and Sonia Seneviratne, professor of ...
Vaccine made from complex of two malaria proteins protects mice from lethal infection
WHAT: An experimental vaccine designed to spur production of antibodies against a key malaria parasite protein, AMA1, was developed more than decade ago by scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. It showed promise in test-tube and animal experiments and in early-stage clinical trials, but returned disappointing results in recent human trials conducted in malaria-endemic countries. Now, the NIAID scientists have improved on their original vaccine with a new candidate that delivers AMA1 ...
Rett syndrome drug shows promise in clinical trial
CAMBRIDGE, MA -- Rett syndrome, a rare genetic disorder that causes mental retardation, autism, and physical deformities, has no cure. However, a small clinical trial has found that a growth factor known as IGF1 can help treat some symptoms of the disease. Children who received the drug for four weeks showed improvements in mood and anxiety, as well as easier breathing, in a trial led by researchers at Boston Children's Hospital. MIT scientists first identified IGF1 as a possible treatment for Rett syndrome in 2009. "This trial shows that IGF1 is safe in the cohort ...
New analysis reveals previously 'hidden diversity' of mouth bacteria
MBL, WOODS HOLE, MA—A new computational method for analyzing bacterial communities has uncovered closely related, previously indistinguishable bacteria living in different parts of the human mouth. The technique, developed by Marine Biological Laboratory (MBL) scientists, provides high taxonomic resolution of bacterial communities and has the capacity to improve the understanding of microbial communities in health and disease. The study will be published in PNAS Online Early Edition the week of June 23-27, 2014. An important step in understanding the role of oral bacteria ...